Abstract
Background: People with Cystic Fibrosis (CF) have decreased exercise capacity and quality of life (HRQoL) compared to the background population. Since 2020 third generation CF transmembrane conductance regulator modulator, elexacaftor, tezacaftor, ivacaftor (ETI) was approved for people with CF from the age of 12 in Denmark. The results of the treatment over short time, show among other increased lungfunction, HRQoL and BMI. The longterm effect regarding the new treatment is to date not fully evaluated especially not regarding exercise capacity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
